Evaluation of ICP-B381 in Patients With Advanced Solid Tumors
An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Jingnan Yang
- 電話番号:010-66609990
- メール:CO-Clinicaltrial@innocarepharma.com
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 募集
- Fudan University Shanghai Cancer Center
-
コンタクト:
- DingWei Ye, M.D.
- 電話番号:021-64175590*81807
- メール:dwyeli@163.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participants must be at least 18 years old.
- Participants thoroughly understand study procedures, and voluntarily sign the written ICF
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
- Expected survival time ≥3 months.
- Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
- Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
- The organ function level must meet the prescribed standards
- All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
- Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
- Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
- Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
- Participants can communicate well with the Investigator and can complete the study according to the study protocol
Exclusion Criteria:
- Other active malignant tumors occurred within 3 years before the first administration of the study drug
- Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
- Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
- Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
- Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
- Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
- Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
- Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
- Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
- Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
- Situations that the investigator deems unsuitable for participating in this study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:ICP-B381
|
ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first). |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
時間枠:2 years
|
2 years
|
|
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
時間枠:2 years
|
2 years
|
|
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
時間枠:2 years
|
2 years
|
|
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
時間枠:2 years
|
2 years
|
|
The optimal dosing regimen for the subsequent study of ICP-B381
時間枠:2 years
|
2 years
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
全生存期間 (OS)
時間枠:2年
|
2年
|
|
応答期間 (DOR)
時間枠:2年
|
2年
|
|
客観的奏効率 (ORR)
時間枠:2年
|
2年
|
|
最大濃度 (Cmax)
時間枠:2年
|
2年
|
|
疾病制御率 (DCR)
時間枠:2年
|
2年
|
|
Time to Maximum Plasma Concentration (Tmax)
時間枠:2 years
|
2 years
|
|
Half-life (T1/2)
時間枠:2 years
|
2 years
|
|
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
時間枠:2 years
|
2 years
|
|
Apparent Clearance Rate (CL/F)
時間枠:2 years
|
2 years
|
|
Terminal Apparent Volume of Distribution (Vz/F)
時間枠:2 years
|
2 years
|
|
Steady-state Pharmacokinetic Parameters
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer: PSA90 response rate
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer:12-week PSA response rate
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer: time to PSA progression (TTPP)
時間枠:2 years
|
2 years
|
|
Time to First Subsequent Therapy (TFST)
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
時間枠:2 years
|
2 years
|
|
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
時間枠:2 years
|
2 years
|
|
Incidence rate of anti-drug antibody (ADA) against ICP-B381
時間枠:2 years
|
2 years
|
|
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
時間枠:2 years
|
2 years
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- ICP-CL-01901
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。